Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 8/20 | 0.44 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854094 | 0.84 | GPR35 (0.72) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7951501 | 0.82 | GPR35 (0.69) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5039555 | 0.82 | GPR35 (0.69) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8346793 | 0.82 | GPR35 (0.69) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9432718 | 0.81 | GPR35 (0.68) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12074964 | 0.80 | GPR35 (0.67) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1310113 | 0.79 | GPR35 (0.68) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14854087 | 0.79 | GPR35 (0.65) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14854212 | 0.79 | GPR35 (0.65) | GPR35HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14902906 | 0.77 | GPR35 (0.62) | GPR35HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027445-A | Transition metal organic compound co-doped conductive material and preparation method thereof | 陕西科技大学 | 2024-05-14 | — | — | CN | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | claimed |
| CN-101309922-A | Amino-aza-adamantane derivatives and methods of use | ABBOTT LAB (US) | 2008-11-19 | — | — | CN | claimed |
| EP-1384713-B1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | claimed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | claimed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | claimed |
| EP-1229912-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | claimed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001034159-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034565-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034154-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | GPR35 63/4885HDAC3 2068/4885HDAC4 2730/4885 |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | GPR35 4470/4885HDAC3 2046/4885HDAC4 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.